Comparative effectiveness of different antiplatelet agents at reducing TNF-driven inflammatory responses in a mouse model
- 1 March 2020
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (3), 432-438
- https://doi.org/10.1111/1440-1681.13211
Abstract
Antiplatelet drugs are conventionally used as treatments because of their anti-coagulation functions. However, their pleiotropic effects are of great significance to the treatment of ischaemic cardiovascular diseases. Many studies have reported that an excessive amount of inflammation driven by tumour necrosis factor (TNF) is closely related to the prevalence of atherosclerosis. As the drug selection criteria and evaluation methods related to the anti-TNF activity of antiplatelet drugs remain limited, our investigation of these drugs should prove beneficial. In this study, we compared the anti-TNF activity of three antiplatelet agents, namely clopidogrel, sarpogrelate, and cilostazol, using the TNF-induced inflammatory mouse model. After the oral administration of these drugs, acute inflammation was induced via injection of lipopolysaccharide (LPS) or D-galactosamine (D-gal) and TNF. Serum TNF levels, and the mRNA and protein expression levels of TNF in mouse heart tissue, macrophage accumulation in aortic lesions, and mouse survival were analysed to compare the anti-TNF effects of the three antiplatelet agents. Of the three antiplatelet agents, cilostazol significantly reduced the different levels under the most effective observation. In addition, cilostazol was found to attenuate the TNF-stimulated phosphorylation of mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cell (NF-kappa B) p65 in the aortic vascular smooth muscle cell line, MOVAS-1 and the D-gal plus TNF-challenged heart tissue of mouse. Therefore, cilostazol is the most ideal of the three antiplatelet drugs for the treatment of TNF-mediated inflammatory disorders.Keywords
This publication has 37 references indexed in Scilit:
- Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated ViewMediators of Inflammation, 2013
- Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 GenotypeJACC: Cardiovascular Interventions, 2011
- Adenosine Diphosphate Receptor Antagonist Clopidogrel Sulfate Attenuates LPS-Induced Systemic Inflammation in a Rat ModelShock, 2011
- Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patientsThrombosis and Haemostasis, 2010
- Role of TNF-α in vascular dysfunctionClinical Science, 2009
- Reduced Albuminuria with Sarpogrelate Is Accompanied by a Decrease in Monocyte Chemoattractant Protein-1 Levels in Type 2 DiabetesClinical Journal of the American Society of Nephrology, 2008
- Cilostazol attenuates MCP‐1 and MMP‐9 expression in vivo in LPS‐administrated balloon‐injured rabbit aorta and in vitro in LPS‐treated monocytic THP‐1 cellsJournal of Cellular Biochemistry, 2007
- The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular riskJournal of Lipid Research, 2007
- Tumor necrosis factor-α as trigger of platelet activation in patients with heart failureBlood, 2005
- Cardiovascular Effects of Serotonin Agonists and AntagonistsJournal of Cardiovascular Pharmacology, 1990